The agreement between the European Union and AstraZeneca to supply 300 million doses of the future vaccine (developed by the manufacturer together with Oxford University) is now official. The European Commission announced on Thursday 27 August that it had signed the advance purchase agreement concluded on 14 August and which is now effective (see EUROPE B12544A6).
Despite this ‘officialisation’, only the main lines of the agreement are known, as it is still classified as...